BCH KOL (consultant to Aevi) treats patients with sirolimus, proof-of-concept for mTOR inhibition in LM
clinical description of KLA (subset of LM), distinct, aggressive pediatric form of LM (PRV eligible)
Disclaimer: These links are being provided as a convenience and for informational purposes only. The views, opinions and conclusions expressed in the links above are those of the authors and do not necessarily reflect the views, opinions and conclusions of the Company. The Company bears no responsibility for the accuracy, legality or content of any external links.